Article
Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis.
Journal of pharmaceutical sciences - 1 Nov 2022
Jeong Seung-Hyun, Jang Ji-Hun, Lee Yong-Bok
Abstract excerpt
Lornoxicam physiologically based pharmacokinetic (PBPK) models were developed and validated on the basis of clinical pharmacokinetic results obtained by considering CYP2C9 genetic polymorphisms in healthy adult populations. PBPK models were extended to predict lornoxicam pharmacokinetics for patients with cirrhosis by quantitatively examining the pathophysiological information associated with cirrhosis. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
